Androgen Receptor Score of Expression and its Correlation with Prognosis in Triple Negative Invasive Breast Cancer

Document Type : Original Article

Authors

1 Oncology Department, Suez Canal Authority Hospitals, Ismailia, Egypt

2 Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt

3 Pathology Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt

4 Clinical Oncology and Nuclear Medicine Department, Suez Canal University, Ismailia, Egypt

Abstract

Introduction: Androgen receptor (AR) is thought to play a crucial role in determining the prognosis of breast cancer patients. No published research that studied score of AR expression and its impact on prognosis. Aim: to correlate the score of expression of AR with the clinicopathological features of triple negative breast cancer patients. Methods: Retrospective-prospective cohort (historical cohort) study of 30 files of breast cancer patients; classified/stratified and tested for Androgen Receptor score of expression, considering time to tumor progression (TTP) as primary end point, and overall survival (OS) as second end points. Results: with a mean follow-up period of 66 months (about 5.5 years), AR intermediate expression (score5) had the best prognosis in triple negative breast cancer female patients; for both TTP and OS (100% had TTP to the 12th year and 100% had OS to the 14th year). Conclusion: Androgen receptor intermediate expression had the best prognosis in triple negative invasive breast cancer female patients. We recommend testing androgen receptors in breast cancer patients whenever feasible; to keep it as a possible target (if positive) in case of failure of the approved lines of treatment.

Keywords

Main Subjects

Suez Canal University Medical Journal
Volume 28, Issue 9
September 2025
Pages 60-76

Files

Share

How to cite

Statistics